Obsidian Therapeutics Announces Closing Of $115 Million Series B Financing
Amount Raised
$115 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareDescription
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a $115 million Series B financing with a premier syndicate of life science investors led by The Column Group Crossover Fund (TCGX). Additional new investors participating in the financing include RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital. Existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb participated in the financing. Also participating in the round is Vertex Pharmaceuticals, with whom Obsidian recently executed a collaboration to discover novel therapies that regulate gene editing.
Quick answer
Obsidian Therapeutics raised $115 Million in a Series B round, dated September 9, 2021. Obsidian Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did Obsidian Therapeutics raise?
- Obsidian Therapeutics raised $115 Million in a Series B round on September 9, 2021.
- What does Obsidian Therapeutics do?
- Obsidian Therapeutics, Inc. is a clinical biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases.
- Where is Obsidian Therapeutics based and how big is it?
- Obsidian Therapeutics is based in Cambridge, Massachusetts, United States. Fundz records about 110 employees.
- Who are the decision-makers at Obsidian Therapeutics?
- Fundz holds 3 contacts at Obsidian Therapeutics, including the Director Regulatory Affairs CMC. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Obsidian Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Trait Biosciences Inc. raised $619K (Seed) on October 22, 2021.
- CHARM Therapeutics raised $13M on October 22, 2021.
- ReCode Therapeutics raised an undisclosed amount (Series B) on October 21, 2021.
- Leucid Bio raised $15M (Series A) on October 21, 2021.
- LifeLens Technologies raised $78K (Pre-Seed) on October 21, 2021.
- Your Super, Inc. raised $1.5M (Seed) on October 20, 2021.
Who to call at Obsidian Therapeutics, and when
A new round usually means Obsidian Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Obsidian Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Obsidian Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Obsidian Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Obsidian Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansObsidian Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.